DarioHealth ( (DRIO) ) has released its Q3 earnings. Here is a breakdown of the information DarioHealth presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
DarioHealth Corp. is a global digital therapeutics company specializing in personalized, evidence-based interventions driven by precision data analytics, software, and personalized coaching, primarily focusing on chronic condition management. In its latest earnings report for the quarter ending September 30, 2025, DarioHealth reported a decrease in total revenues to $5.007 million from $7.423 million in the same period last year. The company continues to face challenges with a net loss of $10.466 million for the quarter, compared to a net loss of $12.330 million in the previous year. Key financial metrics indicate a reduction in operating expenses, which decreased to $12.499 million from $15.907 million year-over-year, reflecting the company’s efforts to streamline operations. Despite the ongoing financial challenges, DarioHealth’s management remains focused on expanding its digital therapeutic solutions and improving its financial health. Looking forward, the company aims to leverage its innovative platform to enhance market penetration and achieve sustainable growth.